All In Biotech

NDA 021265 · Sandoz Canada INC

Infuvite Pediatric (Pharmacy Bulk Package)

Ascorbic Acid, Biotin, Cholecalciferol, Cyanocobalamin, Dexpanthenol, Folic Acid, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol Acetate, Vitamin A, Vitamin K · Intravenous

Last checked: Nov 20, 2026Latest source record: Nov 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Feb 21, 2001

Approved uses

1

Original approval plus efficacy supplements

Registered trials

617

128 Phase 3, 49 recruiting

FAERS reports

24

14 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 20, 2024.

INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 21, 2001 Original approval · Type 5 - New Formulation or New Manufacturer LetterReviewLabel
2 products under this application
  • INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE) · ASCORBIC ACID 80MG/VIAL; BIOTIN 0.02MG/VIAL; CHOLECALCIFEROL 400 IU/VIAL; CYANOCOBALAMIN 0.001MG/VIAL; DEXPANTHENOL 5MG/VIAL; FOLIC ACID 0.14MG/VIAL; NIACINAMIDE 17MG/VIAL; PYRIDOXINE 1MG/VIAL; RIBOFLAVIN 1.4MG/VIAL; THIAMINE 1.2MG/VIAL; TOCOPHEROL ACETATE 7 IU/VIAL; VITAMIN A 2,300 IU/VIAL; VITAMIN K 0.2MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription · TE AP
  • INFUVITE PEDIATRIC · ASCORBIC ACID 80MG/VIAL; BIOTIN 0.02MG/VIAL; CHOLECALCIFEROL 400 IU/VIAL; CYANOCOBALAMIN 0.001MG/VIAL; DEXPANTHENOL 5MG/VIAL; FOLIC ACID 0.14MG/VIAL; NIACINAMIDE 17MG/VIAL; PYRIDOXINE 1MG/VIAL; RIBOFLAVIN 1.4MG/VIAL; THIAMINE 1.2MG/VIAL; TOCOPHEROL ACETATE 7 IU/VIAL; VITAMIN A 2,300 IU/VIAL; VITAMIN K 0.2MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ascorbic Acid" as an intervention, any sponsor and status, largest first.

All 617 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea4
  • cough3
  • erythema3
  • rash generalised3
  • tachycardia3
  • vomiting3
  • anaphylactic reaction2
  • chest discomfort2
  • grunting2
  • hypersensitivity2
  • medication error2
  • paraesthesia2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20091
20111
20122
20141
20165
20181
20191
20201
20215
20221
20241
20251

Recalls

1 FDA enforcement reports for this application.

  • Apr 21, 2020 · Class II · Terminated

    Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,305 on PubMed

Sponsor: Novartis · Also marketed as Infuvite Pediatric

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.